Jenny is a versatile life sciences patent attorney and IP adviser who represents US and international clients in a wide array of patent-related matters. She draws on an in-depth understanding of her clients’ industries and technology to help them protect innovations involving antibodies, cell therapies, gene editing, small molecule therapeutics, pharmaceutical formulations, and diagnostic agents and assays.
Jenny’s practice encompasses US and international patent prosecution, IP due diligence for transactions, clearance analyses, licensing, opinion work, and post-grant proceedings. She has extensive experience with providing strategic counseling on the life-cycle management of both biological and small molecule products.
Prior to joining Mintz, Jenny practiced patent law for more than 15 years, most recently as a partner at an international law firm.
Earlier in her career, as a Harvard Medical School postdoctoral fellow, she worked in the laboratory of Dr. David Hafler at Brigham & Women’s Hospital. In that role, she conducted research on T cell activity in autoimmune diseases such as Type I diabetes.
Experience
- Built global patent portfolios covering an antibody product for a multinational pharmaceutical company that obtained marketing approval in various countries.
- Built global patent portfolios covering cell therapy products for a leading gene editing company.
- Conducted a clearance analysis in connection with a multinational pharmaceutical company’s biosimilar drug development.
- Conducted due diligence studies in connection with various biotech transactions.
- Assisted a leading academic institution in securing patent protection for a diagnostic test expected to be used on millions of patients to ascertain risks for adverse drug reactions.
- Demonstrated continuous diligence over an 11-month period in an interference proceeding for a publicly traded biotechnology company.
viewpoints
News & Press
The Best Lawyers in America 2025 Recognizes 184 Mintz Attorneys across 56 Practice Areas
August 15, 2024
187 Mintz attorneys have been recognized by Best Lawyers® in the 2025 edition of The Best Lawyers in America©. Notably, three Mintz attorneys received 2025 “Lawyer of the Year” awards, and 64 firm attorneys were included in the 2025 edition of Best Lawyers: Ones to Watch.
Mintz IP Practice Recognized in 2024 IAM Patent 1000
June 18, 2024
Our Intellectual Property Practice earned national recognition in the 2024 edition of IAM Patent 1000 – The World’s Leading Patent Practitioners. The guide recognized Mintz with four firm-wide rankings and 14 individual attorney recommendations, including a gold ranking for Intellectual Property Chair Michael Renaud.
Mintz Announces Record Member Growth in 2023
December 22, 2023
Mintz proudly announced the election of 13 attorneys to Members and the addition of a record-setting 22 new lateral Members in 2023, with 11 Partners in the newly opened Toronto office. This diverse group strengthens Mintz’s core areas, spanning Commercial and IP Litigation, Life Sciences, Tech, Private Equity, and Energy & Sustainability. The elevated Members and new lateral additions bring invaluable expertise to help clients navigate complex legal landscapes.
Mintz Adds IP Partner From McDermott In Boston
October 26, 2023
Law360 detailed the arrival of IP Partner Y. Jenny Chen PhD to Mintz’s life sciences practice in Boston.
BOSTON – Y. Jenny Chen, PhD has joined Mintz as a Member in the firm’s highly-regarded Intellectual Property (IP) practice, adding further expertise and depth to the firm’s life sciences offering.
Events & Speaking
Recognition & Awards
Legal 500 for Patents: Prosecution (2024)
Best Lawyers in America: Patent Law (2022 – 2025)
Massachusetts Super Lawyers: Rising Star – Intellectual Property (2014 – 2016)
Identified in the IAM Patent 1000 for Prosecution (2021– 2024)
Involvement
- Member, American Bar Association
- Member, American Intellectual Property Law Association
- Member, Boston Patent Law Association